What question did this study set out to answer?

To determine whether depleting IgE in the airway mucosa with omalizumab reduces airway inflammation and methacholine hyperresponsiveness in allergic asthma.

June 7, 2004American Journal of Respiratory and Critical Care Medicine

Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma

View Full Paper

Ask AI

Bookmark

Authors

RDRatko DjukanovićUniversità Cattolica del Sacro Cuore SWSusan J. WilsonHealth Canada MKMonica KraftUniversity of Arizona

Discussion

Member takes

Overview

Placebo-controlled trial demonstrates omalizumab reduces mucosal and sputum inflammation in allergic asthma, indicating anti-inflammatory benefits despite unchanged methacholine responsiveness.

Key Points

To determine whether depleting IgE in the airway mucosa with omalizumab reduces airway inflammation and methacholine hyperresponsiveness in allergic asthma.
Placebo-controlled trial in 45 patients (N=45) with mild to moderate persistent asthma exhibiting sputum eosinophilia of ≥2%.
Participants received either omalizumab (n=22) or placebo (n=23) for 16 weeks.
Outcomes assessed included inflammatory cell profiles in induced sputum and bronchial biopsies, along with methacholine responsiveness.
Mean sputum eosinophils decreased significantly from 6.6% to 1.7% in the omalizumab arm (p < 0.001), representing a significantly greater reduction compared to placebo (8.5% to 7.0%, p = 0.05).
Omalizumab treatment significantly lowered airway tissue eosinophils, high-affinity IgE receptor-bearing cells, T cells (CD3+, CD4+, CD8+), B cells, and interleukin-4-staining cells.
Airway hyperresponsiveness to methacholine showed no significant improvement after 16 weeks of omalizumab therapy.

Cite This Study

Djukanović et al. (2004) studied this question.

synapsesocial.com/papers/6a709032febe604dd70955ce https://doi.org/10.1164/rccm.200312-1651oc

View Full Paper

Ask AI

Bookmark

June 7, 2004American Journal of Respiratory and Critical Care Medicine

Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma

View Full Paper

Ask AI

Bookmark

Authors

RDRatko DjukanovićUniversità Cattolica del Sacro Cuore SWSusan J. WilsonHealth Canada MKMonica KraftUniversity of Arizona

Discussion

Member takes

Overview

Placebo-controlled trial demonstrates omalizumab reduces mucosal and sputum inflammation in allergic asthma, indicating anti-inflammatory benefits despite unchanged methacholine responsiveness.

Key Points

To determine whether depleting IgE in the airway mucosa with omalizumab reduces airway inflammation and methacholine hyperresponsiveness in allergic asthma.
Placebo-controlled trial in 45 patients (N=45) with mild to moderate persistent asthma exhibiting sputum eosinophilia of ≥2%.
Participants received either omalizumab (n=22) or placebo (n=23) for 16 weeks.
Outcomes assessed included inflammatory cell profiles in induced sputum and bronchial biopsies, along with methacholine responsiveness.
Mean sputum eosinophils decreased significantly from 6.6% to 1.7% in the omalizumab arm (p < 0.001), representing a significantly greater reduction compared to placebo (8.5% to 7.0%, p = 0.05).
Omalizumab treatment significantly lowered airway tissue eosinophils, high-affinity IgE receptor-bearing cells, T cells (CD3+, CD4+, CD8+), B cells, and interleukin-4-staining cells.
Airway hyperresponsiveness to methacholine showed no significant improvement after 16 weeks of omalizumab therapy.

Cite This Study

Djukanović et al. (2004) studied this question.

synapsesocial.com/papers/6a709032febe604dd70955ce https://doi.org/10.1164/rccm.200312-1651oc

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark